免疫学合作与授权交易（2016-2024）

本报告调查2016年至2024年期间与免疫学相关的862项合作与授权交易，交易总数的趋势，金融交易条款，以及交易活跃度最高的25 家公司的趋势、合约文件目录等。

主要优点

本报告为读者提供了以下主要好处：

• 了解2016年以来的合约趋势
• 查看业务伙伴交易
• 基准分析：确定交易的市场价值
• 财务状况
• 交易清单：依公司名称（A-Z）、治疗领域和技术类型
• 主要交易（金额基础）
• 最活跃的谈判者
• 每笔交易的资产识别和交易条件
• 取得合约文件：深入了解交易结构
• 实质审查：评估拟议交易条款对合作伙伴公司的适用性
• 节省数百小时的研究时间

合约分析允许实质审查：

• 授予/选择了哪些权利？
• 合约授予了哪些权利？
• 授予哪些类型的专有权？
• 合约的付款结构为
• 如何审核销售和付款？
• 合约期限为
• 合约的主要条款是如何定义的？
• 如何对待和拥有知识产权？
• 谁负责商业化？
• 谁负责开发、供应和製造？
• 如何管理保密和发布？
• 如何解决争议？
• 什么情况下可以取消合约？
• 如果所有者发生变化会怎样？
• 已就哪些从属许可或分包条款达成协议？
• 公司需要哪些样板条款？
• 哪些样板条款看起来有所不同，取决于合作伙伴和交易类型？
• 每家公司对契约法主张哪一个管辖权？

目录

执行摘要

第1章 简介

第2章 免疫学相关交易趋势

• 免疫学相关交易：年度趋势
• 免疫学相关交易：依交易类型
• 免疫学相关交易：依行业分类
• 免疫学相关交易：依开发阶段
• 免疫学相关交易：依技术类型
• 免疫学相关交易：依适应症分类

第3章 免疫学相关交易：金融交易条件

• 财务条款的揭露
• 标题金额
• 预付款
• 里程碑
• 特许权使用费率

第4章 免疫学相关交易：主要业务伙伴及交易

• 最活跃的交易者
• 最活跃交易者名单
• 主要交易：以交易金额

第5章 免疫学相关交易：合约文件目录

• 合约文件：可用

第6章 免疫相关交易：依治疗标靶

• 免疫相关交易：依治疗目标分类
• 交易目录
• 交易目录：依公司划分（2016-2024年）
• 交易目录：依技术类型分类（2016-2024年）
• 交易类型的定义
• 关于Biopharma Research Ltd
• 目前的合作关係
• 当前合约
• Current Partnering 最近的报告标题

Immunology Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the immunology deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of 862 immunology deals from 2016 to 2024.

The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of collaboration and licensing deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of immunology dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in immunology dealmaking.

Chapter 3 covers the financial deal terms for deals signed in the immunology field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.

Chapter 4 provides a review of the top 25 most active biopharma companies in immunology dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive and detailed review of immunology deals signed and announced since 2016 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of immunology deals listed by theraeutic target.

The report also includes numerous table and figures that illustrate the trends and activities in immunology deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Immunology Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2016
• Browse immunology collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, therapy focus and technology type
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Immunology Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of immunology trends and structure of deals entered into by leading biopharma companies worldwide.

Immunology Collaboration and Licensing Deals includes:

• Trends in immunology dealmaking in the biopharma industry
• Overview of collaboration and licensing deal structure
• Directory of immunology deal records covering pharmaceutical and biotechnology
• The leading immunology deals by value
• Most active immunology licensing dealmakers

In Immunology Collaboration and Licensing Deals, the available deals are listed by:

• Company A-Z
• Headline value
• Therapeutic area
• Technology type
• Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
• Immunology Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in immunology dealmaking

• 2.1. Introduction
• 2.2. Immunology partnering over the years
• 2.3. Immunology partnering by deal type
• 2.4. Immunology partnering by industry sector
• 2.5. Immunology partnering by stage of development
• 2.6. Immunology partnering by technology type
• 2.7. Immunology partnering by therapeutic indication

Chapter 3 - Financial deal terms for immunology partnering

• 3.1. Introduction
• 3.2. Disclosed financials terms for immunology partnering
• 3.3. Immunology partnering headline values
• 3.4. Immunology deal upfront payments
• 3.5. Immunology deal milestone payments
• 3.6. Immunology royalty rates

Chapter 4 - Leading immunology deals and dealmakers

• 4.1. Introduction
• 4.2. Most active in immunology partnering
• 4.3. List of most active dealmakers in immunology
• 4.4. Top immunology deals by value

Chapter 5 - Immunology contract document directory

• 5.1. Introduction
• 5.2. Immunology partnering deals where contract document available

Chapter 6 - Immunology dealmaking by therapeutic target

• 6.1. Introduction
• 6.2. Deals by immunology therapeutic target
• Deal directory
• Deal directory - Immunology deals by company A-Z 2016 to 2024
• Deal directory - Immunology deals by technology type 2016 to 2024
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Immunology partnering since 2016
• Figure 2: Immunology partnering by deal type since 2016
• Figure 3: Immunology partnering by industry sector since 2016
• Figure 4: Immunology partnering by stage of development since 2016
• Figure 5: Immunology partnering by technology type since 2016
• Figure 6: Immunology partnering by indication since 2016
• Figure 7: Immunology deals with a headline value
• Figure 8: Immunology deals with upfront payment values
• Figure 9: Immunology deals with milestone payment
• Figure 10: Immunology deals with royalty rates
• Figure 11: Active immunology dealmaking activity since 2016
• Figure 12: Top immunology deals by value since 2016